Parkinson Disease

Parkinson disease is a progressive neurodegenerative disorder defined neuropathologically by loss of dopaminergic neurons in the substantia nigra pars compacta and by intracellular aggregates of alpha-synuclein known as Lewy bodies and Lewy neurites. The depletion of nigrostriatal dopamine underlies its characteristic motor features.

Definition

Parkinson disease is a neurodegenerative synucleinopathy characterised by progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta and by intraneuronal alpha-synuclein aggregates (Lewy bodies and Lewy neurites), producing a movement disorder dominated by bradykinesia, rigidity, and rest tremor.

Scope

The entry covers the defining pathology of Parkinson disease - nigral dopaminergic neuron loss and alpha-synuclein (Lewy) pathology - and the proposed anatomical staging of how that pathology spreads through the brain. It is a reference and educational overview and does not provide diagnostic or treatment guidance.

Core questions

• Which neuronal population degenerates in Parkinson disease, and what is the molecular hallmark of its pathology?
• How does Lewy (alpha-synuclein) pathology spread through the nervous system?
• Why does loss of nigrostriatal dopamine produce the characteristic motor syndrome?

Key concepts

• Substantia nigra pars compacta degeneration
• Dopaminergic neuron loss
• Alpha-synuclein and Lewy bodies
• Lewy neurites
• Nigrostriatal pathway and dopamine depletion
• Synucleinopathy
• Selective neuronal vulnerability

Key theories

Braak staging of Parkinson-related pathology

Proposes that alpha-synuclein (Lewy) pathology in sporadic Parkinson disease follows a predictable caudal-to-rostral progression, beginning in the lower brainstem and olfactory structures and ascending to the substantia nigra and ultimately the cortex, paralleling the emergence of motor and later non-motor features.

Mechanisms

The core lesion of Parkinson disease is progressive loss of pigmented dopaminergic neurons in the substantia nigra pars compacta, visible grossly as depigmentation of the nigra. Surviving neurons in affected regions contain Lewy bodies and Lewy neurites - aggregates whose principal constituent is misfolded alpha-synuclein - placing the disease among the synucleinopathies. Degeneration of the nigrostriatal projection depletes dopamine in the striatum, disrupting basal-ganglia motor circuits and producing bradykinesia, rigidity, and rest tremor. The Braak staging scheme proposes that the underlying alpha-synuclein pathology spreads in an ascending pattern, which has been linked to the appearance of non-motor features before and after the motor syndrome becomes apparent.

Clinical relevance

The pathology of nigral dopaminergic loss and alpha-synuclein aggregation explains the motor syndrome that characterises Parkinson disease and frames how it is understood and classified. This entry is for reference and education; it describes disease mechanisms and is not a guide to diagnosis or treatment.

Epidemiology

Parkinson disease is one of the most common neurodegenerative disorders and a growing contributor to the global burden of neurological disease, with prevalence increasing with age and rising worldwide as populations age.

Evidence & guidelines

The anatomical progression of Parkinson-related pathology is described in the Braak staging scheme, and contemporary reviews synthesise the molecular and clinical understanding of the disease. Burden estimates draw on the Global Burden of Disease neurological-disorders analyses.

History

The clinical syndrome was described in the early nineteenth century as the shaking palsy. Identification of substantia nigra degeneration and striatal dopamine deficiency clarified the basis of the motor disorder, and the later recognition of alpha-synuclein as the major component of Lewy bodies, together with Braak's staging of pathological spread, shaped the modern neuropathological account.

Debates

Does Parkinson pathology follow a single ascending staging scheme?

Braak's proposal of an orderly caudal-to-rostral spread of alpha-synuclein pathology is influential, but not all cases conform to the predicted sequence, and the universality and mechanism of this staging - including ideas about spreading of misfolded synuclein - remain debated.

Key figures

• Heiko Braak
• Kelly Del Tredici

Seminal works

• braak-2003
• bloem-2021

Frequently asked questions

What is the hallmark pathology of Parkinson disease?

Loss of dopaminergic neurons in the substantia nigra pars compacta together with intraneuronal alpha-synuclein aggregates called Lewy bodies and Lewy neurites. Depletion of nigrostriatal dopamine underlies the motor features.

What is a synucleinopathy?

A synucleinopathy is a neurodegenerative disease characterised by abnormal aggregation of the protein alpha-synuclein; Parkinson disease is a synucleinopathy because its Lewy bodies are composed chiefly of misfolded alpha-synuclein. This is a descriptive classification.